NovaBridge Biosciences(NBP)Earnings, Financials & Key Ratios
NBP•NASDAQ
Price updated Jun 19, 2026
AboutNovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.Show more
- Revenue$0-100.0%
- EBITDA-$373M+26.5%
- Net Income-$162M+88.9%
- EPS (Diluted)-4.46+74.7%
- ROE-16.91%+72.7%
NBP Key Insights
NovaBridge Biosciences (NBP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Share count reduced 2.5% through buybacks
✗Weaknesses
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NBP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NBP Price & Volume
NovaBridge Biosciences (NBP) stock price & volume — 10-year historical chart
Loading chart...
NBP Growth Metrics
NovaBridge Biosciences (NBP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM92.35%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM89.41%
Return on Capital
10 Years-31.1%
5 Years-18.42%
3 Years-19.37%
Last Year-31.21%
NBP Recent Earnings
NovaBridge Biosciences (NBP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (40%)
Q2 2026Latest
Apr 7, 2026Metric
Actual
Est
EPS
$0.22-528.6%
$0.04
Rev
—
—
Q2 2026
Apr 2, 2026Metric
Actual
Est
EPS
$0.03-529.0%
$0.01
Rev
—
—
Q4 2025
Dec 18, 2025Metric
Actual
Est
EPS
$0.25-1801.1%
$0.01
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.01+76.5%
$0.04
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 7, 2026 | $0.22vs $0.04-528.6% | — |
| Q2 2026 | Apr 2, 2026 | $0.03vs $0.01-529.0% | — |
| Q4 2025 | Dec 18, 2025 | $0.25vs $0.01-1801.1% | — |
| Q4 2025 | Nov 12, 2025 | $0.01vs $0.04+76.5% | — |
Based on last 12 quarters of dataView full earnings history →
NBP Peer Comparison
NovaBridge Biosciences (NBP) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 VERA | 2.52B | 35.09 | -7.53 | -74.86% | 0.13 | |||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 |
Compare NBP vs Peers
NovaBridge Biosciences (NBP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NBP Income Statement
NovaBridge Biosciences (NBP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 11.56M | 53.78M | 30M | 1.54B | 88.03M | -10.7M | 4.49M | 0 | 0 |
Revenue Growth % | - | 365.39% | -44.22% | 5042.23% | -94.29% | -112.15% | 141.93% | -100% | -100% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 46.43M | 27.24M | 0 | 0 | 216.28K |
COGS % of Revenue | - | - | - | - | 52.75% | -254.62% | - | - | - |
Gross Profit | 11.56M▲ 0% | 53.78M▲ 365.4% | 30M▼ 44.2% | 1.54B▲ 5042.2% | 41.59M▼ 97.3% | -248.8M▼ 698.2% | 4.49M▲ 101.8% | 0▼ 100.0% | -216.28K▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 47.25% | 2325.83% | 100% | - | - |
Gross Profit Growth % | - | 365.39% | -44.22% | 5042.23% | -97.3% | -698.16% | 101.8% | -100% | - |
Operating Expenses | 310.58M | 461.42M | 1.51B | 1.39B | 2.11B | 355.38M | 515.65M | 375.36M | 34.74M |
OpEx % of Revenue | 2687.63% | 857.95% | 5031.76% | 89.92% | 2400.31% | -3322.17% | 11495.09% | - | - |
Selling, General & Admin | 25.44M | 66.39M | 654.55M | 402.41M | 899.94M | 199.88M | 63.91M | 216.46M | 21.46M |
SG&A % of Revenue | 220.11% | 123.45% | 2181.84% | 26.09% | 1022.36% | -1868.47% | 1424.67% | - | - |
Research & Development | 267.07M | 426.03M | 840.41M | 984.69M | 190.29M | 155.51M | 114.36M | 158.9M | 13.28M |
R&D % of Revenue | 2311.14% | 792.15% | 2801.38% | 63.83% | 216.18% | -1453.7% | 2549.35% | - | - |
Other Operating Expenses | 0 | 0 | 14.56M | 0 | 1.02B | -247 | 337.38M | 0 | 0 |
Operating Income | -280.95M▲ 0% | -438.64M▼ 56.1% | -1.46B▼ 234.0% | 155.57M▲ 110.6% | -2.07B▼ 1431.4% | -366.08M▲ 82.3% | -511.16M▼ 39.6% | -375.36M▲ 26.6% | -34.74M▲ 0% |
Operating Margin % | -2431.25% | -815.6% | -4883.23% | 10.08% | -2353.06% | 3422.17% | -11395.09% | - | - |
Operating Income Growth % | - | -56.12% | -233.98% | 110.62% | -1431.43% | 82.33% | -39.63% | 26.57% | - |
EBITDA | -279.32M | -431.9M | -1.46B | 168.31M | -2.06B | -364.66M | -507.79M | -373.45M | -33.25M |
EBITDA Margin % | -2417.11% | -803.07% | -4850.46% | 10.91% | -2337.41% | 3408.94% | -11319.94% | - | - |
EBITDA Growth % | - | -54.62% | -236.92% | 111.57% | -1322.44% | 82.28% | -39.25% | 26.46% | 87.64% |
D&A (Non-Cash Add-back) | 1.63M | 6.74M | 9.83M | 12.74M | 13.78M | 1.42M | 3.37M | 1.91M | 216K |
EBIT | -44.82M | -56.61M | -207.09M | 155.57M | -2.07B | -52.65M | -347.62M | -375.36M | -33.47M |
Net Interest Income | -732.92K | -1.03M | 3.94M | 3.56M | 21.33M | 4.95M | 7.2M | 54.64M | 8.02M |
Interest Income | 131.42K | 668.26K | 4.37M | 3.71M | 21.33M | 4.95M | 7.3M | 54.64M | 8.02M |
Interest Expense | 864.34K | 1.7M | 427.48K | 146.48K | 0 | 0 | 101.85K | 0 | 0 |
Other Income/Expense | -17.29M | 37.53M | 13.02M | 327.58M | -260.73M | -607.09M | -954.53M | 12.63M | 8.41M |
Pretax Income | -298.24M▲ 0% | -401.11M▼ 34.5% | -1.45B▼ 262.0% | 483.15M▲ 133.3% | -2.33B▼ 582.7% | -973.17M▲ 58.3% | -1.47B▼ 50.6% | -362.73M▲ 75.3% | -26.33M▲ 0% |
Pretax Margin % | -2580.82% | -745.82% | -4839.83% | 31.32% | -2649.26% | 9097.35% | -32674.02% | - | - |
Income Tax | 0 | 1.72M | 0 | 12.23M | -494.81K | 697K | -1.26B | 0 | 0 |
Effective Tax Rate % | 0% | -0.43% | 0% | 2.53% | 0.02% | -0.07% | 85.89% | 0% | 0% |
Net Income | -298.24M▲ 0% | -402.83M▼ 35.1% | -1.49B▼ 268.6% | 470.92M▲ 131.7% | -2.33B▼ 595.1% | -2.51B▼ 7.5% | -1.47B▲ 41.5% | -162.26M▲ 88.9% | -24.54M▲ 0% |
Net Margin % | -2580.82% | -749.02% | -4950% | 30.53% | -2648.7% | 23438.9% | -32674.02% | - | - |
Net Income Growth % | - | -35.07% | -268.64% | 131.71% | -595.11% | -7.54% | 41.54% | 88.93% | 92.35% |
Net Income (Continuing) | -45.68M | -58.56M | -207.52M | 470.92M | -2.33B | -2.51B | -206.77M | -362.73M | -26.33M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200.47M | 1000K |
Minority Interest | 305.71M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -5.13▲ 0% | -6.92▼ 34.9% | -25.53▼ 268.9% | 6.90▲ 127.0% | -30.68▼ 544.6% | -30.38▲ 1.0% | -17.62▲ 42.0% | -4.46▲ 74.7% | -0.24▲ 0% |
EPS Growth % | - | -34.89% | -268.93% | 127.03% | -544.64% | 0.98% | 42% | 74.69% | 89.41% |
EPS (Basic) | -5.13 | -6.92 | -25.53 | 8.07 | -30.70 | -30.38 | -17.62 | -4.46 | - |
Diluted Shares Outstanding | 58.17M | 58.17M | 58.17M | 68.36M | 75.96M | 82.52M | 83.23M | 81.19M | 100.95M |
Basic Shares Outstanding | 58.17M | 58.17M | 58.17M | 68.25M | 75.93M | 82.52M | 83.19M | 81.19M | 100.95M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
NBP Balance Sheet
NovaBridge Biosciences (NBP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 691.59M | 2.04B | 1.36B | 5.34B | 4.78B | 3.63B | 2.34B | 176.69M | 232.78M |
Cash & Short-Term Investments | 574.17M | 1.84B | 1.17B | 733.21M | 670.96M | 3.45B | 2.29B | 173.4M | 228.27M |
Cash Only | 307.93M | 1.59B | 1.14B | 4.76B | 3.52B | 3.21B | 2.14B | 68.26M | 228.06M |
Short-Term Investments | 266.25M | 255.96M | 32M | 31.53M | 753.16M | 235.43M | 20.22M | 105.14M | 210K |
Accounts Receivable | 628.15K | 9.36M | 7.99M | 71.31M | 60.95M | 4.81M | 1.83M | 1.17M | 926K |
Days Sales Outstanding | 19.84 | 63.55 | 97.15 | 16.87 | 252.74 | -164.17 | 149.15 | - | - |
Inventory | 0 | -215.57M | -55.87M | 0 | 4.27M | -80.28M | 28.95M | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | 33.59 | - | - | - | - |
Other Current Assets | 114.86M | 218.85M | 238.85M | 4.53B | 4.03B | 242.96M | 15.68M | 0 | 0 |
Total Non-Current Assets | 333.75M | 339.08M | 376.25M | 990.13M | 847.71M | 447.19M | 276.3M | 35.99M | 44.63M |
Property, Plant & Equipment | 22.34M | 27.66M | 46.5M | 40.27M | 158.5M | 123.97M | 5.55M | 3.8M | 3.17M |
Fixed Asset Turnover | 0.52x | 1.94x | 0.65x | 38.31x | 0.56x | -0.09x | 0.81x | - | 0.00x |
Goodwill | 162.57M | 162.57M | 162.57M | 162.57M | 162.57M | 162.57M | 0 | 0 | 0 |
Intangible Assets | 148.84M | 148.84M | 148.84M | 120.44M | 119.67M | 118.89M | 16.66M | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 664.83M | 380.34M | 30.85M | 1.69M | 30.82M | 136.44M |
Other Non-Current Assets | 0 | 0 | 18.33M | 2.01M | 26.63M | 10.91M | 252.39M | 1.36M | 1.15M |
Total Assets | 1.03B▲ 0% | 2.38B▲ 131.7% | 1.74B▼ 26.9% | 6.33B▲ 264.5% | 5.63B▼ 11.1% | 4.07B▼ 27.6% | 2.61B▼ 35.9% | 212.68M▼ 91.9% | 277.41M▲ 0% |
Asset Turnover | 0.01x | 0.02x | 0.02x | 0.24x | 0.02x | -0.00x | 0.00x | - | 0.00x |
Asset Growth % | - | 131.72% | -26.87% | 264.52% | -11.12% | -27.64% | -35.86% | -91.86% | -91.2% |
Total Current Liabilities | 195.14M | 346.16M | 588.48M | 576.13M | 624M | 659.74M | 411.81M | 8.45M | 16.09M |
Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Payables Outstanding | - | - | - | - | - | - | - | - | - |
Short-Term Debt | 99M | 80M | 50M | -34.8M | 0 | 2.75M | 29.97M | 0 | 872K |
Deferred Revenue (Current) | 15.8M | 14.15M | 3.92M | 9.93M | 2.37M | 2.19M | 1.58M | 106K | 106K |
Other Current Liabilities | 67.33M | 195.74M | 281.28M | 507.51M | -3.45M | 549.85M | -1.12M | 0 | -872K |
Current Ratio | 3.54x | 5.88x | 2.31x | 9.28x | 7.66x | 5.50x | 5.67x | 20.90x | 14.47x |
Quick Ratio | 3.54x | 6.51x | 2.41x | 9.28x | 7.66x | 5.62x | 5.60x | 20.90x | 14.47x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 1.13B | 2.98B | 3.18B | 130.52M | 417.63M | 405.6M | 483M | 3.07M | 2.4M |
Long-Term Debt | 114.01M | 67.03M | 68.2M | 5.54M | 112.45M | 0 | 58.91M | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 7.49M | 5.54M | 81.79M | 32.07M | 23.1M | 3.07M | 10.95M |
Deferred Tax Liabilities | 0 | 0 | 0 | -8.97M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.02B | 2.92B | 3.11B | 119.44M | -610K | 373.53M | 400.99M | 520 | 0 |
Total Liabilities | 1.33B | 3.33B | 3.77B | 706.65M | 1.04B | 1.07B | 894.81M | 11.52M | 18.5M |
Total Debt | 213.01M | 147.03M | 132.5M | 13.6M | 112.45M | 38.29M | 133.87M | 3.88M | 3.27M |
Net Debt | -94.92M | -1.44B | -1B | -4.75B | -3.41B | -3.18B | -2.01B | -64.38M | -224.79M |
Debt / Equity | 36.02x | - | - | 0.00x | 0.02x | 0.01x | 0.08x | 0.02x | 0.01x |
Debt / EBITDA | - | - | - | 0.08x | - | - | - | - | -0.10x |
Net Debt / EBITDA | - | - | - | -28.19x | - | - | - | - | 6.76x |
Interest Coverage | -325.05x | -258.01x | -3426.98x | 1062.06x | - | - | -5018.58x | - | - |
Total Equity | 5.91M▲ 0% | -955.1M▼ 16252.6% | -2.03B▼ 113.0% | 5.63B▲ 376.6% | 4.59B▼ 18.5% | 3.01B▼ 34.4% | 1.72B▼ 42.9% | 201.16M▼ 88.3% | 258.92M▲ 0% |
Equity Growth % | - | -16252.61% | -113.03% | 376.56% | -18.47% | -34.43% | -42.89% | -88.29% | -175% |
Book Value per Share | 0.10 | -16.42 | -34.98 | 82.31 | 60.40 | 36.46 | 20.64 | 2.48 | 2.56 |
Total Shareholders' Equity | -299.8M | -955.1M | -2.03B | 5.63B | 4.59B | 3.01B | 1.72B | 201.16M | 258.92M |
Common Stock | 6K | 6K | 6K | 114K | 126K | 132K | 18.76K | 19K | 27K |
Retained Earnings | -357.86M | -1.01B | -2.49B | -2.02B | -4.35B | -6.77B | -8.33B | -1.29B | -1.3B |
Treasury Stock | -1K | -1K | 0 | 0 | 0 | -21.25M | -56.8M | -6.22M | -5.24M |
Accumulated OCI | 5.69M | 59.38M | 70.13M | -50.79M | -186.51M | 216.72M | 39.77M | 33.38M | 42.89M |
Minority Interest | 305.71M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NBP Cash Flow Statement
NovaBridge Biosciences (NBP) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -252.16M | -280.7M | -867.98M | 433.56M | -973.09M | -1.1B | -72.85M | -52.65M | 1.85M |
Operating CF Margin % | -2182.04% | -521.94% | -2893.27% | 28.1% | -1105.46% | 10309.24% | -1624.1% | - | - |
Operating CF Growth % | - | -11.32% | -209.22% | 149.95% | -324.44% | -13.33% | 93.39% | 27.73% | 0% |
Net Income | -298.24M | -402.83M | -1.45B | 470.92M | -2.33B | -2.51B | -208.18M | -49.7M | -24.54M |
Depreciation & Amortization | 1.63M | 6.74M | 15.63M | 23.14M | 34.14M | 63.82M | 1.06M | 978K | 216.28K |
Stock-Based Compensation | 7.04M | 3.52M | 366.89M | 493.46M | 608.61M | 357.15M | 10.26M | -1.95M | 15.65M |
Deferred Taxes | 8.53M | -75.03M | -6.39M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 3.83M | 38.97M | 23.04M | -313.31M | 321.18M | 431.48M | 161.2M | 809K | 88.09M |
Working Capital Changes | 25.04M | 147.93M | 184.79M | -240.64M | 394.52M | 552.06M | -37.2M | -2.81M | 7.01M |
Change in Receivables | 0 | -11M | 11M | -130.5M | 97.42M | 33.08M | 0 | 0 | -1.44M |
Change in Inventory | 0 | 0 | 0 | 0 | -27.24M | 27.24M | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 107.85M | 0 | 0 | 0 | 0 |
Cash from Investing | -157.66M | 9.5M | 212.46M | -201.9M | -727.21M | 458.38M | -107.63M | -135.97M | -50.62K |
Capital Expenditures | -20.33M | -14.41M | -12.24M | -8.01M | -29.93M | -45.83M | -164.35K | -48K | 3 |
CapEx % of Revenue | 175.9% | 26.79% | 40.8% | 0.52% | 34% | -428.43% | 3.66% | - | - |
Acquisitions | 93.33M | 0 | -224.7M | -257.65M | -6M | 0 | 0 | 0 | -23 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -230.67M | 23.91M | 224.7M | 52M | 0 | 26K | -107.47M | 62K | 0 |
Cash from Financing | 758.59M | 1.48B | 152.71M | 3.44B | 593.92M | 42.36M | -8.25M | -334.89K | 60.87M |
Debt Issued (Net) | 111.31M | 59.7M | 0 | -7.65M | 0 | 2.75M | 0 | 0 | 0 |
Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 0 | -1000K | -1000K | -335K | 1000K |
Dividends Paid | 0 | 0 | -5.28M | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -5.34M | 0 | -3.08M | -8.66M | -335K | 0 |
Other Financing | 594.2M | 1.23B | 131.76M | 2.91B | 593.92M | 60.86M | 407.88K | 0 | -967.91K |
Net Change in Cash | 348.63M▲ 0% | 1.27B▲ 263.8% | -487.65M▼ 138.5% | 3.57B▲ 831.2% | -1.24B▼ 134.6% | -212.86M▲ 82.8% | -151.58M▲ 28.8% | -233.76M▼ 54.2% | 62.66M▲ 0% |
Free Cash Flow | -272.48M▲ 0% | -295.11M▼ 8.3% | -880.22M▼ 198.3% | 425.55M▲ 148.3% | -1B▼ 335.7% | -1.15B▼ 14.5% | -73.02M▲ 93.6% | -52.72M▲ 27.8% | 1.85M▲ 0% |
FCF Margin % | -2357.94% | -548.73% | -2934.08% | 27.59% | -1139.46% | 10737.67% | -1627.76% | - | - |
FCF Growth % | - | -8.31% | -198.27% | 148.35% | -335.7% | -14.52% | 93.64% | 27.8% | - |
FCF per Share | -4.68 | -5.07 | -15.13 | 6.22 | -13.20 | -13.92 | -0.88 | -0.65 | 0.02 |
FCF Conversion (FCF/Net Income) | 0.85x | 0.70x | 0.58x | 0.92x | 0.42x | 0.44x | 0.05x | 0.32x | -0.08x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 710.39K | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 1.42M | 103K | 0 | 0 | 0 |
NBP Key Ratios
NovaBridge Biosciences (NBP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | 26.22% | -45.65% | -66.02% | -62.02% | -16.91% | -9.48% |
Return on Invested Capital (ROIC) | - | - | 13.23% | -150.93% | -54.41% | - | - | -29.43% |
Gross Margin | 100% | 100% | 100% | 47.25% | 2325.83% | 100% | - | - |
Net Margin | -749.02% | -4950% | 30.53% | -2648.7% | 23438.9% | -32674.02% | - | - |
Debt / Equity | - | - | 0.00x | 0.02x | 0.01x | 0.08x | 0.02x | 0.01x |
Interest Coverage | -258.01x | -3426.98x | 1062.06x | - | - | -5018.58x | - | - |
FCF Conversion | 0.70x | 0.58x | 0.92x | 0.42x | 0.44x | 0.05x | 0.32x | -0.08x |
Revenue Growth | 365.39% | -44.22% | 5042.23% | -94.29% | -112.15% | 141.93% | -100% | -100% |
Related:NBP Dividend History·NBP Revenue History·NBP Price History·NBP P/E History·NBP Financial Ratios·NBP Institutional Holders
NBP Frequently Asked Questions
NovaBridge Biosciences (NBP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NovaBridge Biosciences (NBP) saw revenue decline by 100.0% over the past year.
NovaBridge Biosciences (NBP) reported a net loss of $24.5M for fiscal year 2024.
Dividend & Returns
NovaBridge Biosciences (NBP) has a return on equity (ROE) of -16.9%. Negative ROE indicates the company is unprofitable.
NovaBridge Biosciences (NBP) generated $1.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.